🇺🇸 FDA

Company profile · Sponsor

RIGEL

RIGEL PHARMACEUTICALS INC

RIGL · NYSE pharma SOUTH SAN FRANCISCO, CA, USA
Pipeline
24
Drugs
3
Patents
8

Quick answer

RIGEL (RIGL) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

Company facts

Ticker RIGL
Exchange NYSE
Company type pharma
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001034842

Pipeline (24)

Search pipeline →

  1. Fostamatinib

    RIGEL

    Covid19

    phase 3 small molecule completed

    1 trial

  2. Fostamatinib disodium

    RIGEL

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    2 trials

  3. Fostamatinib disodium

    RIGEL

    Immune Thrombocytopenic Purpura

    phase 3 small molecule completed

    3 trials

  4. Fostamatinib

    RIGEL

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  5. Fostamatinib

    RIGEL

    Myelofibrosis

    phase 2 small molecule terminated

    1 trial

  6. Fostamatinib 150 mg

    RIGEL

    IGA Nephropathy

    phase 2 small molecule completed

    1 trial

  7. Fostamatinib 150 mg bid

    RIGEL

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  8. Fostamatinib Disodium

    RIGEL

    T Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  9. Fostamatinib Disodium (R935788)

    RIGEL

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  10. Fostamatinib Disodium / R935788

    RIGEL

    Purpura, Thrombocytopenic, Idiopathic

    phase 2 small molecule completed

    1 trial

  11. Fostamatinib Disodium tablet 100 mg

    RIGEL

    IGA Nephropathy

    phase 2 small molecule terminated

    1 trial

  12. Fostamatinib disodium (R935788)

    RIGEL

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  13. LY3871801

    RIGEL

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  14. Olutasidenib

    RIGEL

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  15. Olutasidenib

    RIGEL

    Mutant IDH1 Inhibitor Olutasidenib

    phase 2 small molecule active

    1 trial

  16. Olutasidenib

    RIGEL

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  17. Olutasidenib

    RIGEL

    Targeted Therapy

    phase 2 small molecule active

    1 trial

  18. Olutasidenib

    RIGEL

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  19. Olutasidenib + TMZ

    RIGEL

    High Grade Glioma

    phase 2 small molecule active

    1 trial

  20. Placebo

    RIGEL

    Acute Respiratory Distress Syndrome

    phase 2 small molecule active

    1 trial

  21. Placebo

    RIGEL

    Asthma

    phase 2 small molecule completed

    1 trial

  22. R348 Ophthalmic Solution, 0.2%

    RIGEL

    Keratoconjunctivitis Sicca

    phase 2 small molecule completed

    2 trials

  23. R348 Ophthalmic Solution, 0.2%

    RIGEL

    Chronic Graft-versus-host Disease

    phase 2 small molecule completed

    1 trial

  24. R788

    RIGEL

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

Drugs (3)

Search drugs →

  1. fostamatinib disodium

    TAVALISSE

    ORAL approved

  2. olutasidenib

    REZLIDHIA

    ORAL approved

  3. pralsetinib

    GAVRETO

    ORAL approved

    L01EX23

Patents (8)

Search patents →

  1. US 12384775

    Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12357623

    Method for treating a disease or condition using a pyrazole compound or formulation thereof

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12331036

    Heterocyclic RIP1 kinase inhibitors

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12297202

    RIP1K inhibitors

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12263180

    Method for treatment of COVID-19-associated conditions

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12227508

    TGF-β inhibitors

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12156880

    Heterocyclic RIP1 kinase inhibitors

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12116354

    RIP1 inhibitory compounds and methods for making and using the same

    Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is RIGEL?

RIGEL (RIGL) is a pharma company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 3 drugs, and 8 patents to this profile..

What pipeline programs does RIGEL sponsor?

We track 24 ClinicalTrials.gov-linked programs for RIGEL, including Fostamatinib and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does RIGEL company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.